Palliative Medicine
January 22, 2024
Louis Plourde, Sue-Ling Chang, Houman Farzin et al.
22 citations
A survey of 2,800 adults in four Canadian provinces found high social acceptability of psilocybin-assisted therapy for existential distress at the end of life. 79.3% considered it a reasonable medical choice, 84.8% agreed public health insurance should cover it, and 63.3% would support legalization for medical purposes. More favorable attitudes were linked to prior psilocybin use, exposure to palliative care, and progressive political orientation. The findings suggest public support is strong enough to help mobilize resources and improve access to this emerging therapy in palliative and end-of-life care.
Palliative Medicine Reports
April 17, 2025
Michel Dorval, Sue-Ling Chang, Houman Farzin et al.
3 citations
A forum in Quebec, Canada, with 57 participants including patients, healthcare professionals, researchers, and policymakers, produced 16 recommendations for expanding access to psilocybin-assisted psychotherapy in palliative care. The recommendations address patient eligibility and equity, regulatory frameworks and respect for autonomy, logistical and organizational aspects, professional education and training, public awareness and information, and research. The report suggests these recommendations could guide similar efforts in other jurisdictions facing barriers to this therapy.
Healthcare (Basel, Switzerland)
June 3, 2026
Michel Dorval, Virginie Audet-Croteau, Sue-Ling Chang et al.
After one year of offering psilocybin-assisted therapy (PAT) at a Canadian university-affiliated tertiary care center, no patients had received the treatment despite clinicians and managers viewing it favorably. Interviews with ten professionals identified administrative and regulatory procedures, along with logistical constraints, as key barriers, while perceived clinical relevance and institutional leadership were facilitators. The estimated cost of delivering a complete PAT intervention ranged from 2,648 to 5,827 Canadian dollars per patient, excluding the cost of psilocybin itself. The gap between regulatory authorization and actual service uptake highlights the need for structured implementation strategies, sustained institutional support, and alignment between regulatory frameworks and clinical workflows.